Corvus Pharmaceuticals, Inc. Shareholders' Equity
Corvus Pharmaceuticals, Inc. (CRVS) had Shareholders' Equity of $225.33 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $225.33M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $240.68M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $61.20M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $71.77M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $225.33M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $240.68M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $61.20M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $71.77M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $80.23M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $49.33M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $32.57M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $12.41M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $51.23M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $33.36M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $38.68M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $44.29M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $49.48M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $48.87M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $56.12M 10-K · filed 2026-03-12 | |
| 2022-09-30 | $64.68M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $80.39M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $89.72M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $97.16M 10-K · filed 2025-03-25 | |
| 2021-09-30 | $105.15M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $96.40M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $94.39M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $72.15M 10-K · filed 2024-03-19 | |
| 2020-09-30 | $42.35M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $50.84M 10-Q · filed 2021-11-01 | |
| 2020-03-31 | $60.03M 10-Q · filed 2021-11-01 | |
| 2019-12-31 | $71.11M 10-K · filed 2023-03-28 | |
| 2019-09-30 | $80.41M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $89.65M 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $100.70M 10-Q · filed 2020-10-29 | |
| 2018-12-31 | $110.34M 10-K · filed 2022-03-10 | |
| 2018-09-30 | $118.85M 10-Q · filed 2019-10-29 | $118.85M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $127.40M 10-Q · filed 2019-10-29 | |
| 2018-03-31 | $137.23M 10-Q · filed 2019-10-29 | |
| 2017-12-31 | $84.83M 10-K · filed 2021-03-25 | |
| 2017-09-30 | $93.74M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $104.78M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $118.22M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $132.80M 10-K · filed 2020-03-09 | |
| 2016-09-30 | $142.91M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $151.97M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $152.55M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$31.10M 10-K · filed 2019-03-07 | |
| 2014-12-31 | -$159.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |